Suggested Topics within your search.
Suggested Topics within your search.
Oberturas
6
Musical settings
2
Música Orquestal
2
Música orquestal
2
Operas
2
Sinfonías
2
Biografías
1
Conciertos (Tríos con Piano)
1
Corno (Instrumento musical)
1
Música para Violín, Violonchelo, Piano y Orquesta
1
Música para fagot y clarinete
1
Nonets (Bassoons (2), clarinets (2), horns (2), oboes (2), double bass), Arranged
1
Pintores
1
Variations (English horn, oboes (2))
1
Woodwind trios (English horn, oboes (2))
1
-
1
-
2
-
3
-
4
-
5
-
6by van den Berg, Paul, Ruppert, Martijn, Mesic, Emir, Snelder, Nelleke, Seelmann, Andreas, Heinig, Roland, Joseph, Amer, Garmann, Dirk, Lippert, Joerg, Eissing, Thomas“…METHODS: Nonlinear mixed-effects population pharmacokinetic models were used to analyze the pharmacokinetics in FIDELIO-DKD, sparsely sampled in all subjects receiving finerenone. …”
Published 2021
Get full text
Get full text
Get full text
Online Article Text -
7by Goulooze, Sebastiaan Camiel, Snelder, Nelleke, Seelmann, Andreas, Horvat-Broecker, Andrea, Brinker, Meike, Joseph, Amer, Garmann, Dirk, Lippert, Joerg, Eissing, Thomas“…BACKGROUND: Finerenone is a nonsteroidal selective mineralocorticoid receptor antagonist (MRA) that demonstrated efficacy in delaying the progression of chronic kidney disease (CKD) and reducing cardiovascular events in patients with CKD and type 2 diabetes mellitus in FIDELIO-DKD, where 5734 patients were randomized 1:1 to receive either finerenone or placebo, with a median follow-up of 2.6 years. …”
Published 2021
Get full text
Get full text
Get full text
Online Article Text -
8by Goulooze, Sebastiaan Camiel, Heerspink, Hiddo J. L., van Noort, Martijn, Snelder, Nelleke, Brinker, Meike, Lippert, Joerg, Eissing, Thomas“…We performed dose–exposure–response analyses to determine the effects of finerenone on these surrogates in the presence and absence of sodium glucose co-transporter-2 inhibitors (SGLT2is) using individual patient data from the FIDELIO-DKD study. METHODS: Non-linear mixed-effects population pharmacokinetic/pharmacodynamic models were used to quantify disease progression in terms of UACR and eGFR during standard of care and pharmacodynamic effects of finerenone in the presence and absence of SGLT2i use. …”
Published 2022
Get full text
Get full text
Get full text
Online Article Text -
9by Flack, John M., Agarwal, Rajiv, Anker, Stefan D., Pitt, Bertram, Ruilope, Luis M., Rossing, Peter, Adler, Sharon G., Fried, Linda, Jamerson, Kenneth, Toto, Robert, Brinker, Meike, Farjat, Alfredo E., Kolkhof, Peter, Lawatscheck, Robert, Joseph, Amer, Bakris, George L.Get full text
Published 2023
Get full text
Get full text
Online Article Text -
10by Agarwal, Rajiv, Anker, Stefan D, Filippatos, Gerasimos, Pitt, Bertram, Rossing, Peter, Ruilope, Luis M, Boletis, John, Toto, Robert, Umpierrez, Guillermo E, Wanner, Christoph, Wada, Takashi, Scott, Charlie, Joseph, Amer, Ogbaa, Ike, Roberts, Luke, Scheerer, Markus F, Bakris, George L“…Unlike CREDENCE, the FIDELIO-DKD trial included patients with high albuminuria but excluded patients with symptomatic heart failure with reduced ejection fraction. …”
Published 2021
Get full text
Get full text
Get full text
Online Article Text -
11by Filippatos, Gerasimos, Pitt, Bertram, Agarwal, Rajiv, Farmakis, Dimitrios, Ruilope, Luis M., Rossing, Peter, Bauersachs, Johann, Mentz, Robert J., Kolkhof, Peter, Scott, Charlie, Joseph, Amer, Bakris, George L., Anker, Stefan D.“…AIMS: This prespecified analysis of the FIDELIO‐DKD trial compared the effects of finerenone, a selective non‐steroidal mineralocorticoid receptor antagonist, on cardiorenal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) by history of heart failure (HF). …”
Published 2022
Get full text
Get full text
Get full text
Online Article Text -
12by Rossing, Peter, Burgess, Ellen, Agarwal, Rajiv, Anker, Stefan D., Filippatos, Gerasimos, Pitt, Bertram, Ruilope, Luis M., Gillard, Pieter, MacIsaac, Richard J., Wainstein, Julio, Joseph, Amer, Brinker, Meike, Roessig, Lothar, Scott, Charlie, Bakris, George L.Get full text
Published 2022
Get full text
Get full text
Online Article Text -
13by Rossing, Peter, Agarwal, Rajiv, Anker, Stefan D., Filippatos, Gerasimos, Pitt, Bertram, Ruilope, Luis M., Amod, Aslam, Marre, Michel, Joseph, Amer, Lage, Andrea, Scott, Charlie, Bakris, George L.“…AIMS: Finerenone significantly reduced the risk of kidney and cardiovascular (CV) outcomes in patients with chronic kidney disease and type 2 diabetes in the FIDELIO‐DKD trial (NCT02540993). This exploratory subgroup analysis investigates the effect of glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use on the treatment effect of finerenone. …”
Published 2021
Get full text
Get full text
Get full text
Online Article Text -
14
-
15
-
16by Pattono, Daniele, D’Agui, Elisa, Fidelio, Marta, Griglio, Bartolomeo, Gili, Stefano, Civera, TizianaGet full text
Published 2020
Get full text
Get full text
Online Article Text -
17by Balatti, Galo E., Ambroggio, Ernesto E., Fidelio, Gerardo D., Martini, M. Florencia, Pickholz, MónicaGet full text
Published 2017
Get full text
Get full text
Online Article Text -
18
-
19by Ruggiero, Fernando M., Martínez-Koteski, Natalia, Cavieres, Viviana A., Mardones, Gonzalo A., Fidelio, Gerardo D., Vilcaes, Aldo A., Daniotti, Jose L.Get full text
Published 2023
Get full text
Get full text
Online Article Text -
20by Ruggiero, Fernando M., Martínez-Koteski, Natalia, Cavieres, Viviana A., Mardones, Gonzalo A., Fidelio, Gerardo D., Vilcaes, Aldo A., Daniotti, Jose L.Get full text
Published 2022
Get full text
Get full text
Online Article Text